Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708742 | 0.94 | P2RX3 (0.56) | P2RX3P2RX2POLBMEN1KMT2A | |
| SCHEMBL310958 | 0.87 | P2RX3 (0.61) | P2RX3P2RX2L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1495498 | 0.73 | TDP1 (0.64) | POLBMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL17965442 | 0.72 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL13415725 | 0.70 | CNR2 (0.60) | POLBMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL311473 | 0.70 | P2RX3 (0.62) | P2RX3P2RX2MEN1KMT2AALDH1A1 | |
| SCHEMBL21241138 | 0.70 | TDP1 (0.69) | POLBMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL2271062 | 0.70 | CYP11B1 (0.39) | P2RX3P2RX2POLBMEN1KMT2A | |
| SCHEMBL311221 | 0.69 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL359422 | 0.68 | TP53 (0.61) | MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2445889-B1 | NOVEL BENZOXAZOLONE -SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2445889-B1 | NOVEL BENZOXAZOLONE -SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20120083500-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS | CHEN LI (CN) | 2012-04-05 | — | — | US | disclosed |
| US-20120083500-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS | CHEN LI (CN) | 2012-04-05 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083500-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885POLB 2894/4885 |
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885POLB 3031/4885 |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885POLB 3031/4885 |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885POLB 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.